Fremanezumab: Reducing Migraine Days Safely and Effectively
- 12 hours ago
- 1 min read
Research Summary
A recent study published in Expert Review of Neurotherapeutics examines the real-world effectiveness and safety of fremanezumab for migraine treatment. This systematic review and meta-analysis found that one month after starting fremanezumab, patients experienced an average reduction of nearly 6 monthly migraine days and over 7 monthly headache days. Additionally, Headache Impact Test scores dropped by nearly 7 points. Impressively, about 50% of patients saw a 50% or greater reduction in migraine or headache days within 3 months, with improvements continuing over a year. The treatment's adverse event rate was low, with constipation being the most common side effect.
Study Details
Â
👥 Research Team: Fernández-Bravo-Rodrigo J et al.
đź“š Published In: Expert Rev Neurother
đź“… Publication Date: 2026 Jun 14
Â
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.